The dexamethasone suppression test and antidepressant response in major depression

Jeffrey S. Simon, Dwight Landis Evans, Charles Nemeroff

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We conducted a prospective open pilot study of 34 consecutively admitted patients with the DSM-III diagnosis of MD who were admitted to a general psychiatric unit. Patients underwent a 1 mg DST and were randomly assigned to treatment with either maprotiline or trazodone. Antidepressant dosages were increased as tolerated clinically and according to treatment response. Results: mean final oral doses were 193 mg for maprotiline and 328 mg for trazodone. The mean treatment duration was 4.5 weeks for maprotiline and 5.9 weeks for the trazodone group. Of these 34 patients 44% showed DST nonsuppression (41% maprotiline, 45% trazodone).Seventy-six per cent of the patients responded to treatment (76% for both drugs) as defined by GAS. Eighty-seven per cent of the nonsuppressors responded to treatment (86% maprotiline, 88% trazodone) and 68% of the suppressors responded (70% maprotiline, 67% trazodone). Of the eight treatment non-responders six showed DST suppression. The implications of these findings are discussed.

Original languageEnglish
Pages (from-to)313-317
Number of pages5
JournalJournal of Psychiatric Research
Volume21
Issue number3
DOIs
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Maprotiline
Trazodone
Dexamethasone
Antidepressive Agents
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders
Psychiatry
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

The dexamethasone suppression test and antidepressant response in major depression. / Simon, Jeffrey S.; Evans, Dwight Landis; Nemeroff, Charles.

In: Journal of Psychiatric Research, Vol. 21, No. 3, 01.01.1987, p. 313-317.

Research output: Contribution to journalArticle

@article{0ca7ebb0aaa24c0fa5ab515739935832,
title = "The dexamethasone suppression test and antidepressant response in major depression",
abstract = "We conducted a prospective open pilot study of 34 consecutively admitted patients with the DSM-III diagnosis of MD who were admitted to a general psychiatric unit. Patients underwent a 1 mg DST and were randomly assigned to treatment with either maprotiline or trazodone. Antidepressant dosages were increased as tolerated clinically and according to treatment response. Results: mean final oral doses were 193 mg for maprotiline and 328 mg for trazodone. The mean treatment duration was 4.5 weeks for maprotiline and 5.9 weeks for the trazodone group. Of these 34 patients 44{\%} showed DST nonsuppression (41{\%} maprotiline, 45{\%} trazodone).Seventy-six per cent of the patients responded to treatment (76{\%} for both drugs) as defined by GAS. Eighty-seven per cent of the nonsuppressors responded to treatment (86{\%} maprotiline, 88{\%} trazodone) and 68{\%} of the suppressors responded (70{\%} maprotiline, 67{\%} trazodone). Of the eight treatment non-responders six showed DST suppression. The implications of these findings are discussed.",
author = "Simon, {Jeffrey S.} and Evans, {Dwight Landis} and Charles Nemeroff",
year = "1987",
month = "1",
day = "1",
doi = "10.1016/0022-3956(87)90033-1",
language = "English",
volume = "21",
pages = "313--317",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - The dexamethasone suppression test and antidepressant response in major depression

AU - Simon, Jeffrey S.

AU - Evans, Dwight Landis

AU - Nemeroff, Charles

PY - 1987/1/1

Y1 - 1987/1/1

N2 - We conducted a prospective open pilot study of 34 consecutively admitted patients with the DSM-III diagnosis of MD who were admitted to a general psychiatric unit. Patients underwent a 1 mg DST and were randomly assigned to treatment with either maprotiline or trazodone. Antidepressant dosages were increased as tolerated clinically and according to treatment response. Results: mean final oral doses were 193 mg for maprotiline and 328 mg for trazodone. The mean treatment duration was 4.5 weeks for maprotiline and 5.9 weeks for the trazodone group. Of these 34 patients 44% showed DST nonsuppression (41% maprotiline, 45% trazodone).Seventy-six per cent of the patients responded to treatment (76% for both drugs) as defined by GAS. Eighty-seven per cent of the nonsuppressors responded to treatment (86% maprotiline, 88% trazodone) and 68% of the suppressors responded (70% maprotiline, 67% trazodone). Of the eight treatment non-responders six showed DST suppression. The implications of these findings are discussed.

AB - We conducted a prospective open pilot study of 34 consecutively admitted patients with the DSM-III diagnosis of MD who were admitted to a general psychiatric unit. Patients underwent a 1 mg DST and were randomly assigned to treatment with either maprotiline or trazodone. Antidepressant dosages were increased as tolerated clinically and according to treatment response. Results: mean final oral doses were 193 mg for maprotiline and 328 mg for trazodone. The mean treatment duration was 4.5 weeks for maprotiline and 5.9 weeks for the trazodone group. Of these 34 patients 44% showed DST nonsuppression (41% maprotiline, 45% trazodone).Seventy-six per cent of the patients responded to treatment (76% for both drugs) as defined by GAS. Eighty-seven per cent of the nonsuppressors responded to treatment (86% maprotiline, 88% trazodone) and 68% of the suppressors responded (70% maprotiline, 67% trazodone). Of the eight treatment non-responders six showed DST suppression. The implications of these findings are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0023549414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023549414&partnerID=8YFLogxK

U2 - 10.1016/0022-3956(87)90033-1

DO - 10.1016/0022-3956(87)90033-1

M3 - Article

C2 - 3681765

AN - SCOPUS:0023549414

VL - 21

SP - 313

EP - 317

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

IS - 3

ER -